UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 47

Sortiert nach

Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016

Annals of oncology, 2018-12, Vol.29 (12), p.2288-2295

2018

Link zum Volltext

Verfügbarkeit prüfen

Malignant pleural mesothelioma: new guidelines make us stronger for defeating this disease

Annals of oncology, 2022-02, Vol.33 (2), p.123-125

2022

Link zum Volltext

Verfügbarkeit prüfen

Consensus clustering methodology to improve molecular stratification of non-small cell lung cancer

Scientific reports, 2023-05, Vol.13 (1), p.7759-7759, Article 7759

2023

Link zum Volltext

Verfügbarkeit prüfen

PD-1 receptor outside the main paradigm: tumour-intrinsic role and clinical implications for checkpoint blockade

British journal of cancer, 2023-10, Vol.129 (9), p.1409-1416

2023

Link zum Volltext

Verfügbarkeit prüfen

Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform

Scientific reports, 2022-05, Vol.12 (1), p.8342-8342, Article 8342

2022

Link zum Volltext

Verfügbarkeit prüfen

Addressing the unmet need in lung cancer: The potential of immuno-oncology

Cancer treatment reviews, 2015-06, Vol.41 (6), p.465-475

2015

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of neurokinin-1 receptor antagonists in the prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis

Annals of oncology, 2017-10, Vol.28, p.vi90-vi90

2017

Link zum Volltext

Verfügbarkeit prüfen

MS13.06 Role of Second Line Chemotherapy and New Target Treatment in Recurrent Mesothelioma

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S182-S183

2019

Link zum Volltext

Verfügbarkeit prüfen

P2.04-03 Perceptions and Knowledge of Electronic Smoking Devices among Patients with Solid Tumors and their Care-Givers

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S132-S133

2022

Link zum Volltext

Verfügbarkeit prüfen

1510TiP Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant non-small cell lung cancer (NSCLC) according to TP53 mutational status (TEMPLE-2/NCT05785208)

Annals of oncology, 2023-10, Vol.34, p.S850-S850

2023

Link zum Volltext

Verfügbarkeit prüfen

2266P IMMUcan consortium: Focus on the first results of the non-small cell lung cancer (NSCLC) cohort

Annals of oncology, 2023-10, Vol.34, p.S1164-S1164

2023

Link zum Volltext

Verfügbarkeit prüfen

1355P Clinical trial enrollment among lung cancer patients: A real-world multicenter analysis

Annals of oncology, 2022-09, Vol.33, p.S1158

2022

Link zum Volltext

Verfügbarkeit prüfen

1640TiP PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced b3-thymoma (B3-T) and thymic carcinoma (TC)

Annals of oncology, 2022-09, Vol.33, p.S1291

2022

Link zum Volltext

Verfügbarkeit prüfen

1811P Molecular characterization of epidermal growth factor receptor-mutated (EGFR-m) non-small cell lung cancer (NSCLC) undergoing histological transformation

Annals of oncology, 2021-09, Vol.32, p.S1230-S1231

2021

Link zum Volltext

Verfügbarkeit prüfen

1676P Nutritional assessment in the era of targeted therapies in advanced non-small cell lung cancer (aNSCLC) oncogene-addicted patients

Annals of oncology, 2021-09, Vol.32, p.S1177-S1177

2021

Link zum Volltext

Verfügbarkeit prüfen

1368TiP EPROPA: The European program for routine testing of patients with advanced lung cancer

Annals of oncology, 2021-09, Vol.32, p.S1037-S1038

2021

Link zum Volltext

Verfügbarkeit prüfen

140P Prognostic and predictive value of co-mutational profile in advanced EGFR positive NSCLC patients treated with TKIs

Journal of thoracic oncology, 2021-04, Vol.16 (4), p.S773-S773

2021

Link zum Volltext

Verfügbarkeit prüfen

OA05.03 Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFRTKI and Platinum-Based Chemotherapy: HERTHENA-Lung01

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S53-S54

2023

Link zum Volltext

Verfügbarkeit prüfen

P59.20 Natural History of KRAS Mutant Non-Small-Cell Lung Cancer in the Immunotherapy Era: A Single-Centre Retrospective Study

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S1156-S1157

2021

Link zum Volltext

Verfügbarkeit prüfen

MA12.07 Oncological Procedures and Risk Assessment of COVID-19 in Thoracic Cancer Patients: A Picture From an Italian Cancer Center

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S923-S924

2021

Link zum Volltext

Verfügbarkeit prüfen

1783P Multi-parametric T cells profiling in broncho-alveolar lavage fluid (BAL) and blood from advanced lung cancer patients

Annals of oncology, 2021-09, Vol.32, p.S1219-S1220

2021

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of neurokinin-1 receptor antagonists in the prevention of Chemotherapy-Induced Nausea and Vomiting in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis

Annals of oncology, 2017-09, Vol.28, p.v548-v548

2017

Link zum Volltext

Verfügbarkeit prüfen

EP16.03-011 The European Program for ROutine Testing of Patients with Advanced Lung Cancer (EPROPA) 1 Year Activity

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S590

2022

Link zum Volltext

Verfügbarkeit prüfen

A systematic review and meta-analysis of trials assessing activity of PD-1/PD-L1 immune checkpoint inhibitors (ICIs) for pre-treated advanced malignant mesothelioma (aMM)

Annals of oncology, 2019-12, Vol.30, p.xi28

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(47)

Sprache

Englisch
(47)
Japanisch
(1)

Erscheinungsjahr

n.n

Kollektion

EZB Electronic Journals Library
(46)
Journals@Ovid Complete
(39)
Ingenta
(7)
MEDLINE
(6)
Nature
(3)
IngentaConnect Journals
(2)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(1)
Elsevier ScienceDirect Journals Complete
(1)

3 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

3 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016

Malignant pleural mesothelioma: new guidelines make us stronger for defeating this disease

Consensus clustering methodology to improve molecular stratification of non-small cell lung cancer

PD-1 receptor outside the main paradigm: tumour-intrinsic role and clinical implications for checkpoint blockade

Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform

Addressing the unmet need in lung cancer: The potential of immuno-oncology

Efficacy of neurokinin-1 receptor antagonists in the prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis

MS13.06 Role of Second Line Chemotherapy and New Target Treatment in Recurrent Mesothelioma

P2.04-03 Perceptions and Knowledge of Electronic Smoking Devices among Patients with Solid Tumors and their Care-Givers

1510TiP Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant non-small cell lung cancer (NSCLC) according to TP53 mutational status (TEMPLE-2/NCT05785208)

2266P IMMUcan consortium: Focus on the first results of the non-small cell lung cancer (NSCLC) cohort

1355P Clinical trial enrollment among lung cancer patients: A real-world multicenter analysis

1640TiP PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced b3-thymoma (B3-T) and thymic carcinoma (TC)

1811P Molecular characterization of epidermal growth factor receptor-mutated (EGFR-m) non-small cell lung cancer (NSCLC) undergoing histological transformation

1676P Nutritional assessment in the era of targeted therapies in advanced non-small cell lung cancer (aNSCLC) oncogene-addicted patients

1368TiP EPROPA: The European program for routine testing of patients with advanced lung cancer

140P Prognostic and predictive value of co-mutational profile in advanced EGFR positive NSCLC patients treated with TKIs

OA05.03 Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFRTKI and Platinum-Based Chemotherapy: HERTHENA-Lung01

P59.20 Natural History of KRAS Mutant Non-Small-Cell Lung Cancer in the Immunotherapy Era: A Single-Centre Retrospective Study

MA12.07 Oncological Procedures and Risk Assessment of COVID-19 in Thoracic Cancer Patients: A Picture From an Italian Cancer Center

1783P Multi-parametric T cells profiling in broncho-alveolar lavage fluid (BAL) and blood from advanced lung cancer patients

Efficacy of neurokinin-1 receptor antagonists in the prevention of Chemotherapy-Induced Nausea and Vomiting in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis

EP16.03-011 The European Program for ROutine Testing of Patients with Advanced Lung Cancer (EPROPA) 1 Year Activity

A systematic review and meta-analysis of trials assessing activity of PD-1/PD-L1 immune checkpoint inhibitors (ICIs) for pre-treated advanced malignant mesothelioma (aMM)

Suchergebnisse filtern